
Publikace



Pohled do databáze evidence [publikační činnosti v systému OBD](#) .

Ve výpisu jsou záznamy publikací s afiliací k 3. LF UK

Vybrané publikace kliniky

- Snowden JA, Badoglio M, Labopin M, Giebel S, McGrath E, Marjanovic Z, Burman J, Moore J, Rovira M, Wulfraat NM, Kazmi M, Greco R, Snarski E, **Kozak T**, Kirgizov K, Alexander T, Bader P, Saccardi R, Farge D. [Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases](#). Blood Adv 2017;1:2742-2755
- **Novak J**, Havrda M, **Gaherova L**, Spicka J, **Kozak T**. [Clinical case: idelalisib-induced immunoglobulin flare](#). Immunopharmacol Immunotoxicol 2017;39:251-252.
- Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tj?nnfjord GE, Itälä-Remes MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, **Kozak T**, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH, Niemann CU. [Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia](#). Leuk Lymphoma 2017;58:2356-2362.
- **Novak J**, **Dobrovolny J**, **Brozova J**, Novakova L, **Kozak T**. [Recovery of mucosal-associated invariant T cells after myeloablative chemotherapy and autologous peripheral blood stem cell transplantation](#). Clin Exp Med 2016;16:529-537.
- Bröckelmann PJ, Goergen H, Kohnhorst C, von Tresckow B, Moccia A, **Markova J**, Meissner J, Kerkhoff A, Ludwig WD, Fuchs M, Borchmann P, Engert A. [Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials](#). J Clin Oncol 2017;35:1444-1450.
- Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, **Markova J**, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A. [Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab \(HD18\): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group](#). Lancet Oncol 2017;18:454-463.
- **Mocikova H**, Pytlík R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova L, Trneny M; Czech Lymphoma Study Group. [Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry](#). Leuk Lymphoma 2016;57:2777-2783.
- **Markova J**, Kahraman D, Kobe C, Skopalova M, **Mocikova H**, Klaskova K, Dedeckova K, Eich HT, Böll B, Dietlein M, **Kozak T**. [Role of \[18F\]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone](#). Leuk Lymphoma 2012;53:64-70.

